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Abstract
Background: The prognostic significance of Epstein-Barr virus (EBV) infection in gastric cancer (GC) remains unclear.
Recently, a number of studies have investigated the association between EBV infection and the prognosis of GC
with controversial results. We therefore conducted a meta-analysis to assess its prognostic significance.
Methods: PubMed and EMBASE were searched for studies up to October 1, 2014. We investigated the association
between EBV infection with survival in patients with GC. The pooled hazard ratio (HR) and its 95 % confidence
interval (CI) were calculated to evaluate risk.
Results: A final analysis of 8,336 patients with GC from 24 studies was performed. Our analysis results indicated that
the pooled HR was 0.67 (95 % CI: 0.55–0.79; Z = 11.18, P < 0.001). Subgroup analyses stratified by region revealed
that the protective role of EBV infection only remained in the Asian population (HR: 0.62, 95 % CI: 0.48–0.75; P < 0.001).
When stratified by study quality and statistical methodology, the protective role could also be identified in high quality
studies (HR: 0.67, 95 % CI: 0.55–0.79) and in univariate analysis studies (HR: 0.62, 95 % CI: 0.50–0.74). There was no
evidence of significant heterogeneity and publication bias.
Conclusions: The presence of EBV has a favorable impact on GC patient’s survival, especially in an Asian population.
Future updated studies, especially large-scale randomized controlled studies stratified by region, are warranted as
validation studies.
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Background
Gastric cancer (GC), one of the most common malig-
nant tumors in the digestive tract, is the fourth most
commonly diagnosed cancer and the second leading
cause of cancer-related mortality worldwide [1]. Al-
though the etiology of GC is still ambiguous, infectious
agents have increasingly attracted attention as the mech-
anism of neoplastic transformation [2]. As we all know,
Helicobacter pylori (H. pylori) is the major causative
agent of GC [3]. Another infectious agent, Epstein-Barr
virus (EBV) has also been found to be associated with
GC [4–6]. EBV is a ubiquitous γ-herpes virus, which is
grouped as a member of the herpesviridae family, sub-
family gamma-Herpesvirinae, genus lymphocryptovirus
[7, 8]. Since its discovery in tumor cells of Burkitt’s
lymphoma in 1964 [9], EBV has been detected in a range
of cancers, such as lymphoid neoplasms, nasopharyngeal,
and gastric epithelial malignancies [10]. EBV-associated
gastric carcinoma (EBVaGC) is defined by the presence of
EBV in the GC cells, which represents about 9 % of GC
worldwide [11–14]. Therefore, EBVaGC is identified as a
distinct disease entity consisting of lymphoepithelioma-
like carcinoma (LELC) and conventional adenocarcinoma
[6, 15]. Though LELC has been reported to present a rela-
tively favorable prognosis [16], the prognostic significance
of EBVaGC is still controversial. A recent large-scale study
from Huang SC et al. revealed no difference in survival be-
tween the EBVaGC cases and the EBV-negative cases [17].
Genitsch V et al. reported that there was no significant
survival advantage for EBVaGC overall [18]. In addition,
He Y et al. also drew consistent conclusion [19]. Consider-
ing that a pooled analysis including 13 studies revealed a
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protective role for EBV infection in the prognosis of GC
[20], we conducted an extensive search for articles that
evaluated the association between EBV and the outcome
of GC. Here, a meta-analysis was performed to more
precisely estimate the association between EBV infection
and the prognosis of GC.
Methods
Search strategy and selection criteria
Two electronic databases (i.e., PubMed and EMBASE)
were searched to explore studies (published before 1
October, 2014) that investigated the prognostic signifi-
cance of EBV infection on the prognosis of GC. There
were no geographic or language restrictions. Medical
Subject Headings (MeSH) words used were the following
keywords “Epstein-Barr virus”, “stomach neoplasms”,
“gastric cancer”, “gastric carcinoma”, “prognosis” and “sur-
vival”. We examined the authors’ names and affiliations
carefully to avoid duplicate data or overlapping articles.
Abstracts of articles (n = 535) were checked independently
by two investigators (XCL and JJL) to determine if full text
articles should be obtained (Fig. 1), and disagreements
were resolved by discussion with our research team.
Studies were eligible if survival was analyzed in GC pa-
tients stratified by EBV status. The primary outcome of
interest was overall survival (OS). The meta-analysis was
based on OS at 3 or 5 years that was extracted from
published papers or original patient’s data. OS was de-
fined as the time from GC diagnosis to death or last
follow-up. The eligibility criteria of the studies were as
follows: to present a proven diagnosis of GC in patients;
to provide a sensitive and reliable method for detection
of the existent status of EBV; to evaluate the correlation
between EBV status and patients’ OS; to report a hazard
ratio (HR) and 95 % confidence interval (CI) or sufficient
date to estimate the HR and 95 % CI according to
methods previously described by Parmar et al. [21, 22].
Data extraction
Data were extracted by two investigators (XCL and JJL)
independently using a predefined form. Discrepancies
were resolved by discussion within our research team.
The following data items were recorded from each study:
first author, year of publication, time of follow-up, region,
number of patients with positive and negative tumors,
method of detection, positive rate, results of univariate
and multivariate survival analyses, HRs and 95 % CIs. If
the relevant information was unavailable in the articles,
we emailed the corresponding author for additional data.
Quality assessment
Study quality was assessed independently by two re-
searchers (XCL and PFK) with the Newcastle-Ottawa
quality assessment scale (Additional file 1: Table S1).
Disagreement was resolved by discussion within our
research team. Each study was assessed on three main
categories: selection, comparability and outcome. The
Newcastle-Ottawa Scale (NOS) scores ranged from 0 to 9;
and a score ≥ 6 indicated good quality. As this was a meta-
analysis, we did not include any humans and/or animals.
Our study was approved by the Research Ethics Commit-
tee at the Cancer Center of Sun Yat-sen University.
Statistical analysis
Our research adhered to the Preferred Reporting Items
for Systematic Reviews and Meta-Analyses (PRISMA)
guidelines (Additional file 2: Table S2) [23, 24]. The
effect of EBV infection on OS was measured by HR and
the corresponding 95 % CI. If the 95 % CI for the pooled
HR did not overlap 1, the effect was considered as statisti-
cally significant. At first, a fixed-effects model (the inverse
variance method) was used for calculating pooled HRs.
When significant heterogeneity was detected across
studies, a random-effects model (DerSimonian and Laird
method) was selected. The existence of heterogeneity be-
tween studies was assessed using the Cochrane Q test and
I2 statistic; with PQ < 0.05 and I
2 > 50 % considered to
represent substantial heterogeneity between studies [25].
The HR of each study was estimated by various published
methods [21, 22]. The most accurate method was to re-
trieve the HR and 95 % CI from the reported results. When
the study did not report the 95 % CI, it was calculated by
its P-value or O-E statistic (difference between numbers of
observed and expected events). If the study only provided
OS curves for the two groups, the HR estimate and its
95 % CI were reconstructed by extracting survival rates at
specified times. In addition, there were three studies that
only provided a risk ratio (RR) to evaluate the correlation
between EBV status and patient OS rates. We selected the
studies for further analysis with caution.
Publication bias was evaluated using a funnel plot, Begg’s
test and Egger’s test. An asymmetric plot suggested possible
publication bias. A two-sided p value < 0.05 was considered
statistically significant for the Begg’s test and Egger’s test
[26, 27]. Kaplan-Meier curves were read by Engauge
Digitizer version 4.1 (http://digitizer.sourceforge.net).
Statistical analysis was carried out using Stata software
(version 12.0). All P values were two-sided and the signifi-
cance level was 0.05.
Results
Study selection and characteristics
A total of 535 articles were identified from two electronic
databases, of which 24 studies were included for the meta-
analysis in accordance with the selection criteria (Fig. 1)
[16, 17, 19, 20, 28–48]. The positive rate of EBV varied
from 2.02 % [35] to 33.3 % [36] and the overall EBV
positivity was 9.3 %. Among these studies, 13 studies
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were performed in Asian patients [17, 19, 28–38], five
studies in European patients [39–43] and six studies in
American patients [16, 44–48]. For all 24 studies, the
presence of EBV in cancer cells was assessed by in situ hy-
bridisation for EBV-encoded RNA (EBER), the gold stand-
ard assay for detecting latent infection. Though a part of
excluded studies used other methods for the detection of
EBV, for example polymerase chain reaction-enzyme im-
munoassay (PCR-EIA) [49], no studies were excluded just
because of inappropriate detection method. With the
exclusion of 3 studies that didn’t provide follow-up data
[31, 44, 48], the estimated median follow-up time was
3.9 years. The total number of included patients was 8,336,
ranging from 87 [41, 42] to 1,114 [32] patients per study.
Table 1 summarizes characteristics of all inclusive studies.
Quality assessment and publication bias
The range of quality scores was from five to nine stars
and the median quality score was seven. We defined the
quality score as more than six to indicate a high quality
study (see Additional file 2: Table S2). As shown in
Table 1, 21 of 24 quality scores were categorized as high
quality studies. The other three studies were categorized
as low quality studies [37, 42, 47].
Overall analysis
The main results of this meta-analysis and the hetero-
geneity test are presented in Table 2. Among the 24
studies eligible for the meta-analysis, 15 studies reported
HRs and 95 % CIs [19, 28, 30–38, 41–43, 46, 47], three
provided an RR and 95 % CI [16, 39, 48], two provided
survival curves [34, 40] and four provided sufficient data
to estimate the HR and 95 % CI [17, 29, 44, 45]. Figure 2
shows the forest plot of the effect sizes and 95 % CIs for
each study and the overall value. The pooled HR for OS
in GC patients was 0.67 (95 % CI: 0.55–0.79; Z = 11.18,
P < 0.001) with a fixed-effects model. There was no
significant evidence of heterogeneity across studies
(I2 = 12.8 %, PQ = 0.283). Investigation of publication bias
by a funnel plot showed funnel plots was a slight lean
(Fig. 3), but the judgments were subjective in nature. The
Begg’s test (P = 0.655) and Egger’s test (P = 0.853) were
Fig. 1 Flow chart of articles selection for meta-analysis. Abbreviations: LELC, lymphoepithelioma-like carcinoma
Liu et al. BMC Cancer  (2015) 15:782 Page 3 of 9
Table 1 Characteristics of individual studies included in the meta-analysis
Study Region Year EBV-positive/EBV-negative Statistical methodology HR estimation Study quality score
Gonzalez CA Europe 2003 4/83 UA HR + 95 % CI 6/9
Chow WH Europe 1999 11/76 UA HR + 95 % CI 5/9
Kim RH Asia 2010 18/229 UA HR + 95 % CI 9/9
Gulley ML Americas 1996 11/84 UA HR + 95 % CI 8/9
Corvalán A Americas 2005 22/71 UA HR + 95 % CI 9/9
van Beek J Europe 2004 41/525 UA survival curves 8/9
He Y Asia 2012 21/97 UA HR + 95 % CI 7/9
Herrera-Goepfert R Americas 2005 8/127 UA HR + 95 % CI 5/9
Corvalan A Americas 2001 27/118 UA HR + 95 % CI 6/9
Koriyama C Asia 2007 49/100 UA HR + 95 % CI 8/9
Boysen T Europe 2011 18/168 UA HR + 95 % CI 7/9
Nakao M Asia 2011 20/351 UA HR + 95 % CI 5/9
Sukawa Y Asia 2012 18/204 UA HR + 95 % CI 7/9
Chiaravalli AM Europe 2006 18/78 UA RR + 95 % CI 7/9
Gao Y Asia 2009 21/1018 UA HR + 95 % CI 7/9
Kijima Y Asia 2003 25/334 UA HR + 95 % CI 9/9
Koriyama C Asia 2002 64/128 MA HR + 95 % CI 6/9
Park ES Asia 2009 50/407 MA HR + 95 % CI 7/9
Song HJ Asia 2010 123/405 UA HR + 95 % CI 8/9
Grogg KL Americas 2003 7/103 UA RR + 95 % CI 9/9
Zhao J Asia 2012 80/631 UA survival curves 7/9
Huang SC Asia 2014 51/943 UA HR + 95 % CI 8/9
Lee HS Asia 2004 63/1051 UA HR + 95 % CI 7/9
Truong CD Americas 2009 12/223 MA RR + 95 % CI 8/9
Abbreviations: EBV Epstein-Barr Virus, HR hazard ratio, CI confidence interval, UA univariate analysis, MA multivariate analysis
Table 2 The prognostic significance of Epstein-Barr virus infection in gastric cancer by prespecified study characteristics in different
subgroups
Stratified analysis No. of Studies Test of association Test of heterogeneity
Pooled HR (95 % CI) Z P-value Model X2 P-value I2 (%)
Overall 24 0.67 (0.55,0.79) 11.18 <0.001 fixed-effects model 26.39 0.283 12.8
Region
Asia 13 0.62 (0.48,0.75) 9.18 <0.001 fixed-effects model 19.65 0.074 38.9
Europe 5 0.87 (0.52,1.23) 4.87 <0.001 fixed-effects model 1.37 0.85 0
Americas 6 0.93 (0.53,1.34) 4.53 <0.001 fixed-effects model 1.76 0.881 0
Statistical methodology
Univariate analysis 21 0.62 (0.50,0.74) 9.81 <0.001 fixed-effects model 18.52 0.553 0
Multivariate analysis 3 1.13 (0.76,1.50) 5.95 <0.001 fixed-effects model 1.36 0.506 0
Quality assessment
High quality 21 0.67 (0.55,0.79) 10.93 <0.001 fixed-effects model 25.77 0.174 22.4
Low quality 3 0.83 (0.16,1.51) 2.41 0.016 fixed-effects model 0.4 0.819 0
Abbreviations: EBV Epstein - Barr virus, HR hazard ratio, CI confidence interval
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used to further examine asymmetry of the funnel plot
(Fig. 4). The P values of both tests were > 0.05 respectively,
which suggested no evidence of publication bias.
Subgroup and sensitivity analyses
Subgroup analyses were further performed to evaluate
the effect of EBV infection on OS in GC patients more
comprehensively, and there was no statistically signifi-
cant heterogeneity or publication bias for all subgroup
analyses. The concrete results were as follows: 1) When
we stratified the studies by region, the pooled HR in
Asia was 0.62 (95 % CI: 0.48–0.75; P < 0.001), the pooled
HR in Europe was 0.87 (95 % CI: 0.52–1.23; P < 0.001),
and in Americas 0.93 (95 % CI: 0.53–1.34; P < 0.001).
After including three low-quality studies, the results of
this subgroup analysis were similar (data not shown).
2) When stratified by study quality, the pooled HR
for 21 high-quality studies was 0.67 (95 % CI: 0.55–0.79;
P < 0.001) and the pooled HR for three low-quality studies
was 0.83(95 % CI: 0.16–1.51; P = 0.016). 3) When further
stratified by statistical methodology (univariate ana-
lysis results versus multivariate analysis results), the
pooled HR for the univariate analysis results was 0.62
Fig. 2 The forest plot demonstrates the effect sizes and 95 % confidence intervals (CIs) for each study and overall. Hazard ratios (HRs) with
corresponding 95 % CIs of individual studies and pooled data for the association between Epstein-Barr virus-positive gastric cancer and overall
survival. The forest plot demonstrates the effect sizes and 95 % CIs for each study and overall
Fig. 3 Funnel Plots for Studies. Funnel plots showing the relationship
between the effect size of individual studies (standard error, horizontal
axis) and the precision of the study estimate (hazard ratios for overall
survival, vertical axis) for EBV
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(95 % CI: 0.50–0.74; P < 0.001). However, the pooled HR
for the multivariate analysis results was 1.13 (95 % CI:
0.76–1.50; P < 0.001), with no statistically significant
differences.
Sensitivity analyses were carried out to determine if
modification of the inclusion criteria for this meta-
analysis affected the final results. First, sensitivity ana-
lyses to examine the influence of the individual data set
to the pooled HR were performed by removing any one
study individually and recalculating the pooled HR. The
overall pooled HR and 95 % CI were not affected by a
single study (data not shown), and the rang was from a
low of 0.65 (95 % CI: 0.53–0.77; P < 0.001) to a high of
0.78 (95 % CI: 0.64–0.91; P < 0.001) via omission of the
study by Park et al. [30] and the study by Gao et al. [35],
respectively. Secondly, sensitivity analyses excluding data
from the three studies only providing an RR and 95 %
CI did not change the pooled HR (HR: 0.65; 95 % CI:
0.53–0.77; P < 0.001). Lastly, sensitivity analyses excluding
the studies of which the HRs (95 % CI) were estimated
from the survival curves did not alter the associations
(HR: 0.67; 95 % CI: 0.55–0.79; P < 0.001).
Discussion
In this study, we first overcame limits of size and region
and showed that the presence of EBV has a favorable
impact on GC patient survival.
Camargo MC et al. conducted a pooled analysis in-
cluding 4,599 patients with GC from 13 studies in 2013.
They found EBVaGC had a relative survival advantage
[20]. The result was consistent with our study. However,
there are some differences between these two studies.
First, with the reports of new large sample studies, it is
necessary to combine results to reach a more reliable
conclusion. For example, a recent study including 994
stage I-III GC patients showed that the OS of EBV-
positive patients with GC did not differ from that of
EBV-negative patients [17]. He Y et al. also reported a
similar conclusion [19]. In the current study, we in-
cluded these new studies and had the largest cases
Fig. 4 Publication bias plot for overall survival (a) Egger’s publication bias plot (b) Begg’s funnel plot
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series, a total of 8,336 patients with GC from 24 studies
to explore the association to date. Second, in subgroup
analysis, the conclusion of the subgroup analysis stratified
by region was different [20]. There was an association be-
tween EBV infection and better survival in Asian patients.
It was worth noting that, the protective role of EBV
infection in European and American patients was not
observed even after excluding low quality studies.
However, Camargo MC et al. found that a survival
advantage for EBVaGC was detected in Asia and Europe
rather than Americas. Considering the limited number of
European case series in the pooled analysis, we suggest
our meta-analysis overcame limits of size and region to
drive a more reliable conclusion. To date, the underlying
reasons for these regional differences are still undefined.
However, population differences in genetic factors may
help explain part of the regional differences [50]. Studies
have reported that EBVaGC displayed distinct clinical and
genetic features. In EBVaGC, the prevalent types and vari-
ants of EBV in eastern countries were different from those
in Latin American countries, suggesting that some EBV
sequence variations might be geographically distributed
[51, 52]. In addition, we speculated that there might be
difference in the way of diagnosis and treatment between
Asian and Western countries, though we didn’t find
sufficient information from included studies. By now, the
treament for GC is still ignored of the EBV status [53].
However, several promising therapeutic approaches
are worthwhile to be further explored. A recent study
from Hui KF et al. demonstrated that, the FDA (Food and
Drug Administration)-approved Pan-histone deacetylase
(HDAC) inhibitor romidepsin, which could potently in-
duce EBV lytic cycle and mediate enhanced cell death with
ganciclovir (GCV), might be applied for the treatment of
EBVaGC [54]. Moreover, medical treatment with a de-
methylation agent may have particular merit in the therapy
of EBVaGC, since methylation of the tumor suppressor
gene is also a key abnormality in EBVaGC. Other potential
medical treatment, such as proteosome inhibitor, antiviral
drugs, inhibition of EBV-induced oncogenic cellular signal-
ing pathways and EBV vaccines, may have an important
role in the therapy of EBVaGC [11, 55]. Therefore, it is of
interest whether difference in the way of treatment
between Asian and Western countries impacts survival.
Furthermore, stratified subgroup analyses were per-
formed by study quality and statistical methodology. We
found the protective role of EBV infection in GC
remained statistically significant in high quality studies
and in univariate analysis results. However, the results
of the multivariate analysis limited our conclusions.
Considering that there has been only three multivariate
analyses, our analysis should be viewed with caution.
Our meta-analysis found that patients with EBVaGC
have a significantly better outcome than those with
EBV-negative GC. Though many studies have been con-
ducted to explore this phenomenon, the mechanisms
underlying better outcomes of EBVaGC are still ambigu-
ous, by far. Most cases of EBVaGC exhibit a histology
rich in lymphocyte infiltration [39, 56], which may repre-
sent a relatively preferable prognosis in EBVaGC cases be-
cause of the improved anti-tumor immune response. In
addition, genetic alteration and methylation of the tumor
suppressor gene may be another key mechanism [57, 58].
It may be possible that, as reported in EBV-positive naso-
pharyngeal carcinoma, EBVaGC has a better prognosis in
part because of better response to therapy [59, 60].
Further studies are needed to identify the mechanisms
underlying this prognostic association.
Although we comprehensively evaluated the associ-
ation between EBV and prognosis in GC with reasonable
statistical methods, several limitations of the current
meta-analysis should be addressed. First, we only ex-
plored the effect of EBV infection on OS in GC patients,
and other factors that may contribute to the tumorigen-
esis of GC, such as genetic factors, environmental expo-
sures and hereditary factors, were not considered. It is
necessary to clarify the interactions between these fac-
tors and EBV infection in further studies. Secondly, it is
difficult to acquire original data to remove other possible
confounding factors, such as less p53 abnormal expres-
sion, higher expression of Human Interleukin 1 Beta
(IL-1b) and so on. Thirdly, as we all know, the publicly
accepted TNM system (7th UICC) is the gold standard
to evaluate GC prognosis. In addition, it has been ac-
cepted that EBVaGC is typically located in non-antral
subsites [11]. We are aware of the fact that differences in
tumor location may impact survival, but the paucity of
individual-level data on variables limits further study.
Thus, our conclusion needs to be verified by studies of
multivariate analysis adjusting for clinicopathological
variables.
Conclusions
To our knowledge, this study has the largest case series
by far to explore the potential role of EBV in GC. We
found that EBV infection has a favorable impact on GC
patient survival, especially in the Asian population. Fu-
ture studies, especially large-scale randomized controlled
studies stratified by region, taking into account the clas-
sical well defined prognostic factors, are warranted as
validation studies.
Additional files
Additional file 1: Table S1. Newcastle-Ottawa Quality Assessment
Scale. (PDF 36 kb)
Additional file 2: Table S2. PRISMA 2009 checklist in current
meta-analysis. (DOC 70 kb)
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